Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Assets (2018 - 2025)

Arcturus Therapeutics Holdings' Non-Current Assets history spans 8 years, with the latest figure at $29.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 22.02% year-over-year to $29.7 million; the TTM value through Dec 2025 reached $150.6 million, down 7.37%, while the annual FY2025 figure was $29.7 million, 22.02% down from the prior year.
  • Non-Current Assets reached $29.7 million in Q4 2025 per ARCT's latest filing, down from $33.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $64.4 million in Q3 2023 to a low of $10.8 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $35.8 million, with a median of $40.7 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: skyrocketed 322.36% in 2022, then plummeted 38.13% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $13.9 million in 2021, then soared by 239.67% to $47.1 million in 2022, then dropped by 9.02% to $42.8 million in 2023, then fell by 11.03% to $38.1 million in 2024, then fell by 22.02% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Non-Current Assets are $29.7 million (Q4 2025), $33.1 million (Q3 2025), and $34.8 million (Q2 2025).